NORTHAMPTON, MA / ACCESSWIRE / December 9, 2022 / The National Black College Alumni Hall of Fame Foundation, Inc. (NBCA) is dedicated to the growth and development of historically Black colleges and universities (HBCUs) through scholarships, internships, training, technical assistance, alumni recognition, and programs that encourage humanitarian involvement. With a new grant, Q4HE is expanding Quest's long-term support for the NBCA with a focus on 3 areas of need:
The athletic initiative is designed to integrate with each university's health system to more effectively deliver care and utilize findings to educate students about their overall health and well-being. This integration will enable universities to better analyze campus food and health service systems.
With more than 300,000 students enrolled, HBCUs send nearly 60,000 graduates into the workforce annually. Through Quest's ongoing support, and with this new investment from Q4HE, the NBCA will expand its efforts to help students transform their potential into possibility.
"Quest for Health Equity provides a depth of partnership that will have a real impact on the health of students at HBCUs. Quest's diverse executive team has demonstrated a commitment to our young adults' health and their future wellbeing. Leadership is everything, and we are thankful to Steve Rusckowski and his vision to close the significant gaps in healthcare in this country."
- Tommy Dortch
NBCA Board Chairman and CEO, TWD, Inc.
View additional multimedia and more ESG storytelling from Quest Diagnostics on 3blmedia.com.
Contact Info:
Spokesperson: Quest Diagnostics
Website: http://www.questdiagnostics.com
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$152.93 |
Daily Change: | -1.30 -0.84 |
Daily Volume: | 650,186 |
Market Cap: | US$17.020B |
August 26, 2024 August 21, 2024 August 15, 2024 August 12, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB